US consumer health company Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for ...

Enforcement action will be taken against any company marketing the products for children under the age of 3 or who are at low or moderate risk for tooth decay.

Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when ...

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...

The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial depletion syndrome, the agency announced on Monday. A pair of ...

A global analysis of 125 turmeric supplements across five major markets revealed widespread inconsistencies in labeling, ...

In 1977, I backpacked through Venezuela and recall our bus driver filling his 800-litre fuel tank for just US$20. At that ...

The U.S. military’s campaign against drug cartels has killed 64 people and destroyed 16 boats. Here's when the strikes ...

Over the last decade, clinics have popped up across Southern California and beyond advertising something called magnetic e-resonance therapy, or MERT, as a therapy for autism.

SAN FRANCISCO -- Two studies demonstrated the benefits of treating juvenile myasthenia gravis (MG) with newer drugs.